

## ***Basingstoke, Southampton and Winchester District Prescribing Committee (DPC)***

**Recommendations of the meeting of 11<sup>th</sup> December 2012**

### **Supported or limited support, e.g. specialist recommendation/initiation**

- **Darunavir Liquid** -The Committee endorsed the Chair's recommendation to support the availability of this locally. Prescribing should be retained by HIV and GUM specialists.
- **Budenofalk brand of budesonide m/r capsules** - The DPC endorsed the Chair's recommendation to support the availability of this brand locally.
- **Aquacel foam dressing**- Following discussion the Committee endorsed the Chair's recommendation to support use locally within the niche identified by the Wound Formulary Group, and provided its use is closely monitored.

### **Not Supported currently**

- **Glycopyrronium (special order) products for hyperhidrosis**-The Committee noted its recommendation in December 2011 not to support the use of glycopyrronium solution for iontophoresis. Following further discussion the DPC supported the use of aluminium containing roll-on products (e.g Anhydrol) and propantheline oral preparations, as well as specialist use of botulinum toxin which is supported locally. The Committee reiterated its previous recommendation not to support the use of glycopyrronium topical products for hyperhidrosis.
- **Alicaforsen enemas (unlicensed, orphan drug)** - use is not supported locally due to the lack of evidence of effectiveness in the treatment of both pouchitis and ulcerative colitis.

### **Information / Reminders / Updates/ Safety Messages / NICE**

- **Imiquimod and Actikerall Solution in the primary care treatment of Actinic Keratosis**- Imiquimod is not recommended for local use currently following a review at the August DPC meeting. The place in treatment of Actikerall solution (fluorouracil and salicylic acid) requires further consideration. It has been suggested by local specialists that Actikerall may have a place in the treatment of single keratinised lesions. There are several other new products for AK currently and the DPC agreed to review again shortly, to support updating of the local Map of Medicine pathway.
- **N-acetylcysteine (unlicensed special order product)**-The DPC reiterated its previous recommendation that N-acetylcysteine remains a treatment for idiopathic pulmonary fibrosis and should be considered 'amber' (specialist recommended). A formal shared care guideline is not thought to be necessary.
- **Updated osteoporosis guidelines and denosumab shared care guidelines**- The main changes to the guidelines were noted and approved:
- **Updated acamprosate shared care guidelines**, jointly developed by Southern Health and Solent trusts, were approved, including a 'GP quick reference guide'.
- **Three new respiratory products** have recently been launched. **Acclidinium** (Eklira Genuair) is a twice daily inhaled LAMA for COPD; **glycopyrronium bromide** (Seebri Breezhaler) is a once daily inhaled LAMA for COPD, and **Flutiform** (fluticasone/formoterol) is a combination ICS/LABA for asthma. The constituents of Flutiform are already approved for local use. The place of the other new products is currently under DPC consideration, and a decision will follow as to whether they represent an advance in COPD treatment before local prescribing can be supported.

**Summarised on behalf of the District Prescribing Committee  
Julia Bowey (NHS Southampton City) 18.01.13**